22 results
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
further development of, or deny approval of, TNT119 for any or all targeted indications. The drug-related side effects could affect patient recruitment
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial
10-K
v70e7rj
7 Mar 22
Annual report
4:03pm
10-Q
v6c8p eqn9gs
13 Sep 21
Quarterly report
4:01pm
424B4
twbzlzvsy jyyfcks
11 Aug 21
Prospectus supplement with pricing info
5:05pm
S-1/A
0snlk8
2 Aug 21
IPO registration (amended)
6:08am
S-1
zoxflwv
16 Jul 21
IPO registration
5:02pm
DRS/A
9w1kko djwi0npkhk
12 Jul 21
Draft registration statement (amended)
12:00am